BridgeBio Pharma, Inc. (BBIO) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $206.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $2.16B.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $204.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $2.11B.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $202.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $2.06B.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $200.00K; Additional Paid in Capital, Common StockUSD (m); Additional Paid in CapitalUSD $2.02B.
BridgeBio Pharma, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Treasury Stock, Common, Value USD | Treasury Stock, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Noncontrolling Interest, Decrease from Deconsolidation USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments USD | Treasury Stock, Value, Acquired, Cost Method USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $206.00K | (m) | $2.16B | $533.28M | (m) | $-7.00K | $-4.14B | $-2.52B | $-2.50B | 10.58M | 3 month · $45.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $204.00K | (m) | $2.11B | $405.78M | (m) | $-8.00K | $-3.99B | $-2.28B | $-2.27B | 8.68M | 3 month · $32.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $202.00K | (m) | $2.06B | $323.28M | (m) | $12.00K | $-3.82B | $-2.09B | $-2.08B | 7.60M | 12 month · $140.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $200.00K | (m) | $2.02B | $323.28M | (m) | $2.00K | $-3.63B | $-1.93B | $-1.92B | 7.60M | 3 month · $35.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $198.00K | $1.98B | (m) | (m) | $323.28M | $1.00K | $-3.45B | $-1.79B | $-1.78B | 7.60M | 3 month · $38.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $197.00K | $1.94B | (m) | (m) | $323.28M | $0.00 | $-3.26B | $-1.65B | $-1.64B | 7.60M | 3 month · $32.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $196.00K | $1.90B | $1.90B | $275.00M | $275.00M | $8.00K | $-3.10B | $-1.47B | $-1.46B | 6.19M | 12 month · $112.00M | (m) | 12 month · $179.04M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $195.00K | $1.88B | (m) | (m) | $275.00M | $5.00K | $-2.83B | $-1.23B | $-1.22B | 6.19M | 3 month · $26.65M | (m) | 3 month · $52.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $194.00K | $1.85B | (m) | (m) | $275.00M | $-4.00K | $-2.67B | $-1.09B | $-1.08B | 6.19M | 3 month · $31.50M | 3 month · $164.00K | 3 month · $126.44M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $193.00K | $1.82B | (m) | (m) | $275.00M | $2.00K | $-2.60B | $-1.05B | $-1.04B | 6.19M | 3 month · $27.12M | 3 month · $35.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $181.00K | $1.48B | (m) | (m) | $275.00M | $31.00K | $-2.56B | $-1.35B | $-1.34B | 6.19M | 12 month · $98.60M | (m) | 12 month · $3.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $180.00K | $1.46B | (m) | (m) | $275.00M | $34.00K | $-2.39B | $-1.21B | $-1.20B | 6.19M | 3 month · $24.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $168.00K | $1.13B | (m) | (m) | $275.00M | $63.00K | $-2.22B | $-1.36B | $-1.35B | 6.19M | 3 month · $24.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $167.00K | $1.11B | (m) | (m) | $275.00M | $-12.00K | $-2.06B | $-1.23B | $-1.21B | (m) | 3 month · $24.33M | (m) | 3 month · $3.95M | (m) | (m) | (m) | (m) | (m) | (m) | 6.19M |
| 2022-12-31 | (m) | $157.00K | $938.70M | (m) | (m) | $275.00M | $-328.00K | $-1.92B | $-1.25B | $-1.24B | 6.19M | 12 month · $94.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.19M |
| 2022-09-30 | (m) | $156.00K | $917.33M | (m) | (m) | $275.00M | $-348.00K | $-1.78B | $-1.14B | $-1.13B | (m) | 3 month · $23.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.19M |
| 2022-06-30 | (m) | $154.00K | $892.96M | (m) | (m) | $275.00M | $-427.00K | $-1.64B | $-1.03B | $-1.01B | (m) | 3 month · $23.90M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.19M |
| 2022-03-31 | (m) | $154.00K | $867.60M | (m) | (m) | $275.00M | $-383.00K | $-1.63B | $-1.04B | $-1.04B | (m) | 3 month · $25.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6.19M |
| 2021-12-31 | (m) | $154.00K | $841.53M | (m) | (m) | $275.00M | $-132.00K | $-1.44B | $-870.41M | $-867.00M | (m) | 12 month · $89.82M | (m) | (m) | (m) | 12 month · $200.00M | (m) | (m) | (m) | (m) | 6.19M |
| 2021-09-30 | (m) | $153.00K | $821.22M | (m) | (m) | $275.00M | $19.00K | $-1.29B | $-743.40M | $-738.84M | (m) | 3 month · $16.90M | (m) | (m) | (m) | 3 month · $144.69M | (m) | (m) | (m) | (m) | 6.19M |
| 2021-06-30 | (m) | $153.00K | $799.68M | (m) | (m) | $130.31M | $36.00K | $-1.13B | $-464.29M | $-457.49M | (m) | 3 month · $32.51M | (m) | (m) | (m) | 3 month · $5.31M | (m) | (m) | (m) | (m) | 3.28M |
| 2021-03-31 | (m) | $152.00K | $767.12M | (m) | (m) | $125.00M | $-57.00K | $-1.04B | $-395.29M | $-389.37M | (m) | 3 month · $19.84M | (m) | (m) | (m) | 3 month · $50.00M | (m) | (m) | (m) | (m) | 3.17M |
| 2021-01-01 | (m) | (m) | $853.27M | (m) | (m) | (m) | (m) | $-874.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $125.00K | $1.02B | (m) | (m) | $75.00M | $192.00K | $-888.75M | $57.91M | $106.26M | (m) | 12 month · $36.53M | 12 month · $50.83M | (m) | 12 month · $168.08M | 12 month · $75.00M | (m) | (m) | (m) | (m) | 2.41M |
| 2020-09-30 | (m) | $125.00K | $1.01B | (m) | (m) | $75.00M | $461.00K | $-768.77M | $163.76M | $215.81M | (m) | 3 month · $11.75M | 3 month · $7.27M | (m) | (m) | (m) | 3 month · $11.75M | (m) | (m) | (m) | 2.41M |
| 2020-06-30 | (m) | $125.00K | $992.69M | (m) | (m) | $75.00M | $858.00K | $-652.91M | $265.76M | $325.61M | (m) | 3 month · $7.29M | 3 month · $3.54M | (m) | (m) | (m) | 3 month · $7.29M | (m) | (m) | (m) | 2.41M |
| 2020-03-31 | (m) | $124.00K | $986.75M | (m) | (m) | $75.00M | $726.00K | $-531.88M | $380.71M | $449.02M | (m) | 3 month · $8.06M | 3 month · $26.57M | (m) | 3 month · $167.73M | 3 month · $75.00M | 3 month · $8.06M | (m) | (m) | (m) | 2.41M |
| 2019-12-31 | (m) | $124.00K | $848.11M | (m) | (m) | (m) | $254.00K | $-440.03M | $408.45M | $473.73M | (m) | 12 month · $15.20M | 12 month · $1.21M | (m) | (m) | (m) | 12 month · $3.94M | 12 month · $351.00K | (m) | (m) | 0.00 |
| 2019-09-30 | (m) | $117.00K | $826.06M | (m) | (m) | (m) | $152.00K | $-366.57M | $459.76M | $521.70M | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $3.95M | 3 month · $279.00K | (m) | (m) | (m) |
| 2019-06-30 | (m) | $92.00K | $469.43M | (m) | (m) | (m) | (m) | $-306.59M | $162.93M | $211.32M | (m) | 1 month · $69.00K | (m) | (m) | (m) | (m) | 3 month · $2.19M | (m) | 3 month · $69.00K | (m) | (m) |
| 2019-05-17 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $92.00K | $492.68M | (m) | (m) | (m) | (m) | $-240.63M | $252.14M | $310.46M | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $1.24M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $92.00K | $494.23M | (m) | (m) | (m) | (m) | $-179.44M | $314.88M | $377.24M | (m) | 12 month · $3.18M | 12 month · $55.24M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $165.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $204.37M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $61.69M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $51.00K | $134.50M | (m) | (m) | (m) | (m) | $-48.70M | $85.85M | $88.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $-4.53M | (m) |
| 2016-12-31 | (m) | $21.00K | $33.00M | (m) | (m) | (m) | (m) | $-18.13M | $14.89M | $17.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |